Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 279

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Trial: Protocol for a Randomized, Controlled, Multicenter Study Comparing the Solitaire Revascularization Device with IV tPA with IV tPA Alone in Acute Ischemic Stroke

Open access
Saver, Jeffrey L., Goyal, Mayank, Bonafe, Alain, Diener, Hans-Christoph, Levy, Elad I., Pereira, Vitor M., Albers, Gregory W., Cognard, Christophe, Cohen, David J., Hacke, Werner, Jansen, Olav, Jovin, Tudor G., Mattle, Heinrich P., Nogueira, Raul G., Siddiqui, Adnan H., Yavagal, Dileep R., Devlin, Thomas G., Lopes, Demetrius K., Reddy, Vivek, de Rochemont, Richard du Mesnil, Jahan, Reza, for the SWIFT PRIME Investigators · 2015 · International Journal of Stroke

Abstract

Rationale: Early reperfusion in patients experiencing acute ischemic stroke is critical, especially for patients with large vessel occlusion who have poor prognosis without revascularization. Solitaire™ stent retriever devices have been shown to immediately restore vascular perfusion safely, rapidly, and effectively in acute ischemic stroke patients with large vessel occlusions. Aim: The aim of the study was to demonstrate that, among patients with large vessel, anterior circulation occlusion who have received intravenous tissue plasminogen activator, treatment with Solitaire revascularization devices reduces degree of disability 3 months post stroke. Design: The study is a global multicenter, two-arm, prospective, randomized, open, blinded end-point trial comparing functional outcomes in acute ischemic stroke patients who are treated with either intravenous tissue plasminogen activator alone or intravenous tissue plasminogen activator in combination with the Solitaire device. Up to 833 patients will be enrolled. Procedures: Patients who have received intravenous tissue plasminogen activator are randomized to either continue with intravenous tissue plasminogen activator alone or additionally proceed to neurothrombectomy using the Solitaire device within six-hours of symptom onset. Study Outcomes: The primary end-point is 90-day global disability, assessed with the modified Rankin Scale (mRS). Secondary outcomes include mortality at 90 days, functional independence (mRS ≤ 2) at 90 days, change in National Institutes of Health Stroke Scale at 27 h, reperfusion at 27 h, and thrombolysis in cerebral infarction 2b/3 flow at the end of the procedure. Analysis: Statistical analysis will be conducted using simultaneous success criteria on the overall distribution of modified Rankin Scale (Rankin shift) and proportions of subjects achieving functional independence (mRS 0–2).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ijs.12459

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 8

  1. 10.1161/STROKEAHA.109.562827 · doi:10.1161/strokeaha.109.562827
  2. Jansen O, 1995, AJNR Am J Neuroradiol, 16, 1977
  3. 10.1161/STROKEAHA.114.006487 · doi:10.1161/strokeaha.114.006487
  4. 10.1227/01.neu.0000429859.96652.57 · DOI
  5. 10.1161/STROKEAHA.111.000371 · doi:10.1161/strokeaha.111.000371
  6. 10.1007/s00234-012-1076-y · doi:10.1007/s00234-012-1076-y
  7. 10.1161/STROKEAHA.114.005084 · doi:10.1161/strokeaha.114.005084
  8. 10.1161/STROKEAHA.114.006277 · doi:10.1161/strokeaha.114.006277

Cited by

See all 279

Metadata

Authors
Saver, J. L., Goyal, M., Bonafe, A., Diener, H.-C., Levy, E. I., Pereira, V. M., Albers, G. W., Cognard, C., Cohen, D. J., Hacke, W., Jansen, O., Jovin, T. G., Mattle, H. P., Nogueira, R. G., Siddiqui, A. H., Yavagal, D. R., Devlin, T. G., Lopes, D. K., Reddy, V., de Rochemont, R. D. M., Jahan, R., & for the SWIFT PRIME Investigators
Venue
International Journal of Stroke
Published
2015-03-16
Volume
10
Issue
3
Pages
439-448
ISSN
  • 1747-4930 (ISSN-L)
  • 1747-4949
OpenAlex
W1505941256
Cited by
279
References
13
FWCI
34.86
Type
journal article
Language
en
Open access
green
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Funders
Covidien (NA)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Trial: Protocol for a Randomized, Controlled, Multicenter Study Comparing the Solitaire Revascularization Device with IV tPA with IV tPA Alone in Acute Ischemic Stroke. https://app.cochat.ai/papers/10.1111/ijs.12459
The paper
Saver, J. L., Goyal, M., Bonafe, A., Diener, H.-C., Levy, E. I., Pereira, V. M., Albers, G. W., Cognard, C., Cohen, D. J., Hacke, W., Jansen, O., Jovin, T. G., Mattle, H. P., Nogueira, R. G., Siddiqui, A. H., Yavagal, D. R., Devlin, T. G., Lopes, D. K., Reddy, V., . . . for the SWIFT PRIME Investigators. (2015). Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Trial: Protocol for a Randomized, Controlled, Multicenter Study Comparing the Solitaire Revascularization Device with IV tPA with IV tPA Alone in Acute Ischemic Stroke. International Journal of Stroke. https://doi.org/10.1111/ijs.12459

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.